Chronic myeloid leukemia (CML) has been a “model disease” with a long history. Beginning
with the first discovery of leukemia and the description of the Philadelphia Chromosome and …

From the laboratory perspective, effective management of patients with chronic myeloid
leukemia (CML) requires accurate diagnosis, assessment of prognostic markers, sequential …

Chronic myeloid leukemia (CML) is defined by the presence of Philadelphia chromosome
(Ph) which results from a reciprocal translocation between chromosomes 9 and 22 [t (9; 22] …

Chronic myeloid leukemia (CML) is a clonal myeloproliferative neoplasm driven by BCR-
ABL1 oncoprotein, which plays a pivotal role in CML pathology, diagnosis, and treatment as …

There are different BCR-ABL1 fusion genes that are translated into proteins that are different
from each other, yet all leukemogenic, causing chronic myeloid leukemia (CML) or acute …

Chronic myeloid leukemia (CML) is defined by the presence of Philadelphia chromosome
resulting from a reciprocal translocation between chromosomes 9 and 22 [t9; 22] that gives …

With treatment-free remission (TFR) rapidly becoming the ultimate goal of therapy in chronic
myeloid leukemia (CML), there is a need to develop strategies to maximize sustained TFR …

The most frequent BCR‐ABL1 fusion transcripts in chronic myeloid leukemia (CML) are the
e13a2 (b2a2) and the e14a2 (b3a2) ones. In the imatinib era few studies addressing the …

Background Stopping tyrosine kinase inhibitor (TKI) treatment has become a realistic and
safe objective for patients who have chronic myeloid leukemia (CML). Both a sustained …

Tyrosine-kinase inhibitors have changed the natural history of chronic myeloid leukaemia in
such a way that patients with adequate access to these agents, who are properly managed …